KRAS and neoplasm: The tumor was staged as pT3/pN2/pM0 PPSRCC according to the American Joint Committee on Cancer 8th edition staging system.8 The tumor had KRAS and TP53 mutations, and immunohistochemical (IHC) analysis of mismatch repair proteins revealed retained expression of MLH1, PMS2, MSH2, and MSH6.